ArticleClinicoEconomics and outcomes research : CEOR2015

Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.

Jason R Guertin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.